Nuvectis Pharma Inc.
NVCT | NASDAQ
$22.40
+$0.42 (+1.91%)
Sep 22, 2026, 10:33 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -7.2M | -6.26M | -7.62M | -7.79M | -6.6M | -5.57M | -6.45M | -4.36M | -4.64M | -4.4M | -6.87M | -6.16M | -5.77M | -4.1M | -6.78M | -5.94M | -3.57M | -2.95M | -2.27M | -4.67M | -5.94M | -23K |
Interest Income | 177K | 210K | -829K | 332K | 261K | 236K | 201K | 206K | 215K | 225K | 244K | 277K | 64K | 52K | 82K | 61K | 4K | 2K | 4K | n/a | n/a | n/a |
Pretax Income | -7.02M | -6.05M | -7.31M | -7.46M | -6.33M | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M | -6.62M | -5.88M | -5.71M | -4.05M | -6.7M | -5.88M | -3.57M | -2.94M | -2.26M | -4.67M | -5.94M | -23K |
Net Income | -7.02M | -6.05M | -7.31M | -7.46M | -6.33M | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M | -6.62M | -5.88M | -5.71M | -4.05M | -6.7M | -5.88M | -3.57M | -2.94M | -2.26M | -4.67M | -5.94M | -23K |
Selling & General & Admin | 2.51M | 2.15M | 2.53M | 2.02M | 2.98M | 1.89M | 1.95M | 1.54M | 1.7M | 1.74M | 2.6M | 1.67M | 1.51M | 1.73M | 2.38M | 1.42M | 1.07M | 1.14M | 1.12M | 512K | 1.69M | 23K |
Research & Development | 4.68M | 4.11M | 5.09M | 5.77M | 3.61M | 3.68M | 4.5M | 2.82M | 2.94M | 2.66M | 4.27M | 4.49M | 4.26M | 2.37M | 4.4M | 4.52M | 2.51M | 1.81M | 1.14M | 4.16M | 4.25M | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 7.2M | 6.26M | 7.62M | 7.79M | 6.6M | 5.57M | 6.45M | 4.36M | 4.64M | 4.4M | 6.87M | 6.16M | 5.77M | 4.1M | 6.78M | 5.94M | 3.57M | 2.95M | 2.27M | 4.67M | 5.94M | 23K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 7.2M | 6.26M | 7.62M | 7.79M | 6.6M | 5.57M | 6.45M | 4.36M | 4.64M | 4.4M | 6.87M | 6.16M | 5.77M | 4.1M | 6.78M | 5.94M | 3.57M | 2.95M | 2.27M | 4.67M | 5.94M | 23K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 23.48M | 23.41M | 21.81M | 22.72M | 21.37M | 19.94M | 19.5M | 17.23M | 16.9M | 16.56M | 17.42M | 16.1M | 15.18M | 14.72M | 14.64M | 14.05M | 12.72M | 12.72M | 12.72M | 12.72M | 12.72M | 12.72M |
Shares Outstanding (Diluted) | 23.48M | 23.41M | 21.81M | 22.72M | 21.37M | 19.94M | 19.5M | 17.23M | 16.9M | 16.56M | 17.42M | 16.1M | 15.18M | 14.72M | 14.64M | 14.05M | 12.72M | 12.72M | 12.72M | 12.72M | 12.72M | 12.72M |
EPS (Basic) | -0.30 | -0.26 | -0.31 | -0.44 | -0.30 | -0.27 | -0.34 | -0.24 | -0.26 | -0.25 | -0.42 | -0.37 | -0.38 | -0.27 | -0.50 | -0.42 | -0.28 | -0.32 | -0.21 | -0.39 | -0.47 | 0 |
EPS (Diluted) | -0.30 | -0.26 | -0.31 | -0.44 | -0.30 | -0.27 | -0.34 | -0.24 | -0.26 | -0.25 | -0.42 | -0.37 | -0.38 | -0.27 | -0.50 | -0.42 | -0.28 | -0.32 | -0.21 | -0.39 | -0.47 | 0 |
EBITDA | -7.2M | -6.05M | -8.21M | -7.46M | -6.33M | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M | -6.62M | -5.88M | -5.71M | -4.05M | -6.7M | -5.88M | -3.57M | -2.94M | -2.26M | -4.67M | -5.94M | -23K |
EBIT | -7.2M | -6.05M | -8.21M | -7.46M | -6.33M | -5.33M | -6.25M | -4.15M | -4.43M | -4.17M | -6.62M | -5.88M | -5.71M | -4.05M | -6.7M | -5.88M | -3.57M | -2.94M | -2.26M | -4.67M | -5.94M | -23K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove NVCT